

First Name: Ann  
Last Name: Mertens  
Institution: Emory University  
Address 1: Emory Childrens Center  
Address 2:  
City: Atlanta  
State/Province: GA  
Country:  
Zip: 30322  
Phone: 404-785-0691  
Alternate Phone:  
Email: [amerten@emory.edu](mailto:amerten@emory.edu)

---

Requirements to submit AOI:

---

A comprehensive review of previously published data has been completed.: Yes  
The specific aims are clear and focused.: Yes  
The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator.: Yes  
The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months.: Yes

---

---

Project Title: Differences in participant characteristics and changes in treatment characteristics from the original to the expanded cohorts

Planned research population (eligibility criteria): The original CCSS cohort has been well described. As we begin to examine outcomes in the expanded cohort, it will be important to identify similarities/differences between the two cohorts. In addition, treatment factors in the original CCSS cohort have been well described. Identical medical record abstraction in the expanded cohort will allow treatment factors in this cohort to be well described as well. As we begin to examine outcomes in the expanded cohort, it will be important to note similarities/differences in treatment between the two cohorts.

Proposed specific aims: This proposed analysis will look at demographic and socioeconomic information to determine differences and similarities between the two CCSS cohorts. We propose the following objectives: Objective 1: Determine the characteristics that are similar/different between cohorts, overall and by primary diagnosis. Objective 2: Identify characteristics that may impact outcomes This proposed analysis will also compare specific treatment factors between the two CCSS cohorts. We propose the following objectives: Objective 1: Determine treatment factors that are similar/different between cohorts, overall and by diagnosis group. Objective 2: Identify differences in treatment factors that may impact outcomes

Will the project require non-CCSS funding to complete?: No

If yes, what would be the anticipated source(s) and timeline(s) for securing funding?:

---

Does this project require contact of CCSS study subjects for . . .

---

Additional self-reported information: No

Biological Samples: No

Medical record data: No

If yes to any of the above, please briefly describe.:

---

What CCSS Working Group(s) would likely be involved? (Check all that apply)

---

Second Malignancy:

Chronic Disease:

Psychology / Neuropsychology:

Genetics:

Cancer Control:

Epidemiology / Biostatistics: Primary

---

To describe the anticipated scope of the study, please indicate the specific CCSS data to be included as outcome (primary or secondary) or correlative factors. (Check all that apply)

---

Late mortality: Secondary

Second Malignancy: Secondary

---

Health Behaviors

---

Tobacco: Secondary

Alcohol: Secondary

Physical activity: Secondary

Medical screening: Secondary

Other:

If other, please specify:

---

Psychosocial

---

Insurance: Primary

Marriage:

Education: Primary

Employment: Primary

Other:

If other, please specify:

---

Medical conditions

---

Hearing/Vision/Speech: Secondary

Hormonal systems: Secondary

Heart and vascular: Secondary

Respiratory:

Digestive: Secondary

Surgical procedures: Secondary  
Brain and nervous system: Secondary  
Other: Secondary  
If other, please specify: residence status

---

Medications

---

Describe medications:

---

---

Pregnancy and offspring:  
Family History:

---

Psychologic/Quality of Life

---

BSI-18: Secondary  
SF-36: Secondary  
CCSS-NCQ: Secondary  
PTS:  
PTG:  
Other:  
If other, please specify:

---

---

Chronic conditions (CTCAE v3): Secondary  
Health status:

---

Demographic

---

Age: Secondary  
Race: Secondary  
Sex: Secondary  
Others: Primary  
If others, please specify: Diagnosis factors, alive/dead status, HIPAA consent, treatment type, specific chemotherapy (anthracyclines, alkylating agents, epipodophyllotoxins, bleomycin); specific radiation sites (brain, chest, gonads); specific surgeries (amputations, transplant)

---

Cancer treatment

---

Chemotherapy:  
Radiation therapy:  
Surgery:

---

Anticipated sources of statistical support

---

CCSS Statistical Center:

Local institutional statistician:

If local, please provide the name(s) and contact information of the statistician(s) to be involved.:

Will this project utilize CCSS biologic samples?: No

---

If yes, which of the following?

---

Buccal cell DNA:

Peripheral blood:

Lymphoblastoid cell lines:

Second malignancy pathology samples:

Other requiring collection of samples:

If other, please explain:

---

---

Other general comments: Mertens and Leisenring will be co-leads for this AOI. This AOI is for consideration as a high priority analysis from the Epi/Biostats Working Group